SF3B1 and myelodysplastic syndrome: SF3B1 mutation is considered to be a good prognostic marker in MDS and is associated with the ring-sideroblast (RS) phenotype. SF3B1 mutation is seen in 60-90% of the patients with RS.10 RAS mutation occurs in approximately 10-15% of cases and increases the risk of conversion to AML.